Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison
- 24 March 2018
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (7) , 1637-1642
Abstract
A head-to-head comparison of once-monthly oral bisphosphonates minodronate (MIN) and risedronate (RIS) in patients with rheumatoid arthritis (RA) demonstrated that MIN has the same effect as RIS on increase in bone mineral density (BMD) and a stronger effect on inhibition of bone resorption than RIS, suggesting that MIN is a promising treatment option for osteoporosis patients with RA.Keywords
This publication has 28 references indexed in Scilit:
- Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summaryArchives of Osteoporosis, 2012
- Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosisOsteoporosis International, 2011
- The relationship between the chemistry and biological activity of the bisphosphonatesBone, 2011
- Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporosis International, 2008
- Clinical assessment of the long‐term risk of fracture in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Bisphosphonate therapy in rheumatoid arthritisJoint Bone Spine, 2006
- Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studiesJournal of Bone and Mineral Metabolism, 2004
- Bisphosphonates: mechanisms of actionExpert Opinion on Therapeutic Patents, 2001
- Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three‐year randomized, double‐blind trialArthritis & Rheumatism, 1996
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988